23 results
Thumbnail

- D3.147 - The inhaled PDE4 inhibitor tanimilast shows a broad anti-inflammatory effect in two mouse models of asthma induced by house dust mite

Thumbnail

- D3.148 - Oscillometry and spirometry derived ratios to assess small airways dysfunction in severe asthma patients taking tezepelumab

Thumbnail

D3.149 - Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in a real life clinic setting

Thumbnail

- D3.150 - Effects of benralizumab on T cell adhesion molecules in severe eosinophilic asthma: modulation by IL-25 and IL-33

Thumbnail

- D3.151 - Prevalence and clinical characteristics of adult asthma patients with different phenotype across GINA step 1 to 5 asthma

Thumbnail

D3.152 - Phenotype and treatment response of allergic patients with severe asthma: a real-world experience from Argentina

Thumbnail

- D3.154 - Safety of allergen immunotherapy in patients with severe asthma. A real-world, multicentre, observational retrospective study

Thumbnail

D3.155 - IL-1 signaling pathway molecules as key markers in childhood severe asthma

Thumbnail

- D3.156 - Self-reported asthma symptoms and asthma medication usage in patients with possible asthma: A MASK-air® real-world study

Thumbnail

D3.157 - A study of the detailed patterns of wheeze presence and absence from infancy through to adolescence

Thumbnail

- D3.158 - Clinical and functional profile of children with asthma in a tertiary referral hospital

Thumbnail

D3.159 - Investigation of Huai Qi Huang Granules' Impact and Mechanism on Asthmatic Mice's Antiviral Capability

Thumbnail

- D3.162 - The Effects of Phthalate Exposure on Asthma via Microbiota Changes

Thumbnail

- D3.163 - Mast cell activation test and airway hyperresponsiveness in cat allergy: investigating the link to cat allergen induced asthma

Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix

Thumbnail

D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy